Up-regulation of tyrosine hydroxylase mRNA in a sub-population of A10 dopamine neurons in Parkinson's disease

Molecular Brain Research

Volumn 79, Issue 1-2, 2000, Pages 45-54

  Tong, Zhang Yan ^a   Kingsbury, Ann E ^a   Foster, Oliver J F ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

In situ hybridization; Non melanised neurons; Parkinson's disease; Tyrosine hydroxylase mRNA; Ventral tegmental area

Indexed keywords

DOPAMINE BETA MONOOXYGENASE; MESSENGER RNA; TYROSINE 3 MONOOXYGENASE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; MALE; MELANOGENESIS; NERVE CELL LESION; PARKINSON DISEASE; PRIORITY JOURNAL; VENTRAL TEGMENTUM;

AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; BRAIN; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; LEVODOPA; MALE; NEURONS; ORGAN SPECIFICITY; PARKINSON DISEASE; REFERENCE VALUES; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TYROSINE 3-MONOOXYGENASE; VENTRAL TEGMENTAL AREA;

EID: 0034705456     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-328X(00)00089-9     Document Type: Article

References (55)

1. Agid Y., Javoy F., Glowinski J. Hyperactivity of remaining dopaminergic neurones after partial destruction of the nigra-striatal dopaminergic system in the rat. Nature. 245:1973;150-151.
2. Bannon M.J., Bunney E.B., Roth R.H. Mesocortical dopamine neurons: rapid transmitter turnover compared to other brain catecholamine systems. Brain Res. 218:1981;376-382.
3. Bannon M.J., Roth R.H. Pharmacology of mesocortical dopamine neurons. Pharmacol. Rev. 35:1983;53-68.
4. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 20:1973;415-455.
5. Björklund A., Lindvall O. Catecholaminergic brain stem regulatory systems. Mountcastle V.B., Bloom F.E., Geiger S.R. Handbook of Physiology. Section 1: The Nervous System. Intrinsic Regulatory Systems of the Brain. Vol. IV:1986;155-235 Amer. Physiol. Society, Bethesda.
6. Chiodo L.A., Bannon M.J., Grace A.A., Roth R.H., Bunney B.S. Evidence for the absence of impulse-regulating somatodendritic and synthesis-modulating nerve terminal autoreceptors on subpopulations of mesocortical dopamine neurons. Neuroscience. 12:1984;1-16.
7. Chiodo L.A. Dopamine-containing neurons in the mammalian central nervous system: electrophysiology and pharmacology. Neurosci.Biobehav. Rev. 12:1988;49-91.
8. Dahlström A., Fuxe K. Evidence for the existence of monoamine-containing neurons in the central nervous system. Acta Physiol. Scand. 62:(Suppl. 232):1964;1-80.
9. Daniel S.E., Lees A.J. Parkinson's Disease Society Brain Bank, London: overview and research. J. Neural Transm. 39:(Suppl.):1993;165-172.
10. Deutch A.Y., Goldstein M., Baldino Jr F., Roth R.H. Telencephalic projections of the A8 dopamine cell group. Ann. N.Y. Acad. Sci. 537:1988;27-50.
11. Fahn S., Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann. Neurol. 32:1992;804-812.
12. Fearnley J.M., Lees A.J. Aging and Parkinson's disease: substantia nigra regional selectivity. Brain. 114:1991;2283-2301.
13. Foley J.M., Baxter D. On the nature of pigment granules in the cells of the locus coeruleus and substantia nigra. J. Neuropath. Exp. Neurol. 17:1958;586-598.
14. Gaspar P., Stepniewska I., Kaas J.H. Topography and collateralization of the dopaminergic projections to motor and lateral prefrontal cortex in owl monkeys. J. Comp. Neurol. 325:1992;1-21.
15. German D.C., Mannye K., Smith W.K., Woodward D.J., Saper C.B. Midbrain dopaminergic cell loss in Parkinson's disease: Computer visualization. Ann. Neurol. 26:1989;507-514.
16. Gibb W.R. Melanin, tyrosine hydroxylase, calbindin and substance P in the human midbrain and substantia nigra in relation to nigrostriatal projections and differential neuronal susceptibility in Parkinson's disease. Brain Res. 581:1992;283-291.
17. Graham D.G. On the origin and significance of neuromelanin. Arch. Pathol. Lab. Med. 103:1979;359-362.
18. Halliday G.M., Li Y.W., Blumbergs P.C., Joh T.H., Cotton R.G.H., Howe P.R.C., Blessing W.W., B Geffen L. Neuropathology of Immunochemically identified brainstem neurons in Parkinson's disease. Ann. Neurol. 27:1990;373-385.
19. Hardy J.A., Wester P., Winblad B., Gezelius C., Bring G., Eriksson A. The patients dying after long terminal phase have acidotic brains; implications for biochemical measurements on autopsy tissue. J. Neural. Transm. 61:1985;253-264.
20. Hefti F., Melamed E., Wurtman R.J. Partial lesions of the dopaminergic nigrostriatal system in the brain: Biochemical characterization. Brain Res. 195:1980;95-122.
21. Hirsch E., Graybiel A.M., Agid Y. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature. 334:1988;345-348.
22. O. Hornykiewicz, S.J. Kish, Biochemical pathophysiology of Parkinson's disease, in: M.D. Yahr, K.J. Bergmann (Eds.), Advances in Neurology, Vol. 45, Raven Press, New York, 1986, pp. 19-34.
23. Javoy-Agid F., Agid Y. Is the mesocortical dopaminergic system involved in Parkinson disease? Neurology. 30:1980;1326-1330.
24. Javoy-Agid F., Hirsch E.C., Dumas S., Duyckaerts C., J Mallet Y. Agid, Decreased tyrosine hydroxylase messenger RNA in the surviving dopamine neurons of the substantia nigra in Parkinson's disease: an in situ hybridization study. Neuroscience. 38:1990;245-253.
25. Jellinger K.A. Morphological substrates of dementia in Parkinsonism. A critical update. J. Neural. Transm. Suppl. 51:1997;57-82.
26. Jellinger K.A. Neuropathology of movement disorders. Neurosurg. Clin. North Am. 9:1998;237-262.
27. Joyce J.N., Smutzer G., Whitty C.J., Myers A., Bannon M.J. Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with Parkinsonism, and Alzheimer's disease. Movement Dis. 12:1997;885-897.
28. Kalivas P.W. Neurotransmitter regulation of dopamine neurons in the ventral tegmental area. Brain Res. Rev. 18:1993;75-113.
29. Kastner A., Hirsch E.C., Agid Y., Javoy-Agid F. Tyrosine hydroxylase protein and messenger RNA in the dopaminergic nigra neurons of patients with Parkinson's disease. Brain Res. 606:1993;341-345.
30. Kobayashi K., Kurosawa Y., Fujita K., Nagatsu T. Human dopamine beta-hydroxylase gene: two mRNA types having different 3′-terminal regions are produced through alternative polyadenylation. Nucleic Acid Res. 17:1989;1089-1102.
31. Kemper C.M., O'Connor D.T., Westlund K.N. Immunocytochemical localization of dopamine-â-hydroxylase in neurons of the human brain stem. Neuroscience. 23:1987;981-989.
32. Kingsbury A.E., Foster O.J.F., Nisbet A.P., Cairns N., Bray L., Eve D.J., Lees A.J., Marsden C.D. Tissue pH as an indicator of mRNA preservation in human post-mortem brain. Mol. Brain Res. 28:1995;311-318.
33. Kingsbury A.E., Bray L., Foster O.J.F. A simplified and rapid procedure for in situ hybridization on human, flash-frozen, post-mortem brain and its combination with immunohistochemistry. J. Neurosci. Meth. 69:1996;213-227.
34. Kingsbury A.E., Marsden C.D., Foster O.J.F. The vulnerability of nigral neurons to Parkinson's disease is unrelated to their intrinsic capacity for dopamine synthesis: An in situ hybridization study. Movement Dis. 14:1999;206-218.
35. Moal L., Simon H. Mesocorticolimbic dopaminergic network: functional and regulatory roles. Physiol. Rev. 71:1991;155-234.
36. Mann D.M.A., Yates P.O. Lipoprotein pigments-their relationship to ageing in the human nervous system. II - The melanin content of pigmented nerve cells. Brain. 97:1974;489-498.
37. McRitchie D.A., Hardman C.D., Halliday G.M. Cytoarchitectural distribution of calcium binding proteins in midbrain dopaminergic regions of rats and humans. J. Comp. Neurol. 364:1996;121-150.
38. McRitchie D.A., Cartwright H.R., Halliday G.M. Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson's disease. Exp. Neurol. 114:1997;202-213.
39. Murray A.M., Weihmueller F., Marshall J.F., Hurtig H.I., Gottlieb G.L., Joyce J.N. Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with Parkinsonism. Ann. Neurol. 37:1995;300-312.
40. Nagatsu T. Genes for human catecholamine-synthesizing enzymes. Neurosci. Res. 12:1991;315-345.
41. Oades R.D., Halliday G.M. Ventral tegmental (A10) system: Neurobiology. 1. Anatomy and connectivity. Brain Res. Rev. 12:1987;117-165.
42. Olanow C.W. A radical hypothesis for neurodegeneration. Trends. Neurosci. 16:1993;439-444.
43. Pearson J., Brandeis L., Goldstein M. Appearance of tyrosine hydroxylase immunoreactivity in the human embryo. Dev. Neurosci. 3:1980;140-150.
44. Pearson J., Goldstein M., Markey K., Brandeis L. Human brainstem catecholamien neuronal anatomy as indicated by immunocytochemistry with antibodies to tyrosine hydroxylase. Neuroscience. 8:1983;3-32.
45. Rordriguez M.C., Obeso J.A., Olanow C.W. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: A target for neuroprotection. Ann. Neurol. 44:(3 Suppl. 1):1998;S175-188.
46. Snyder G.L., Keller R.W., Zigmond M.J. Dopamine efflux from striatal slices after intracerebral 6-hydroxydopamine: Evidence for compensatory hyperactivity of residual terminals. J. Pharmacol. Exp. Ther. 253:1990;867-876.
47. Swanson L.W. The projections of the ventral tegmental area and adjacent regions: combined fluorescent retrograde tracer and immunofluorescence study in the rat. Brain Res. Bull. 9:1982;321-353.
48. Swanson L.W., Hartman B.K. The central adrenergic system. An immunofluorescence study of the location of cell bodies and their efferent connections in the rat utilizing dopamine-beta-hydroxylase as a marker. J. Comp. Neurol. 163:1975;467-505.
49. Tsai C. The optic tracts and centers of the opossum, didelphis virginiana. J. Comp. Neurol. 39:1925;173-215.
50. Uhl G.R., Hedreen J.C., Price D.L. Parkinson's disease: loss of neurons from the ventral tegmental area contralateral to therapeutic surgical lesions. Neurology. 35:1985;1215-1218.
51. Ungerstedt U. Stereotaxic mapping of the monoamine pathways in the rat brain. Acta Physiol. Scand. 83:(Suppl. 367):1971;1-48.
52. Waters C.M., Peck R., Rossor M., Reynolds G.P., Hunt S.P. Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson's disease and Huntington's chorea. Neuroscience. 24:1988;419-438.
53. White F.J., Wang R.Y. A10 dopamine neurons: Role of autoreceptors in determining firing rate and sensitivity to dopamine agonists. Life Sci. 34:1984;1161-1170.
54. Williams S.M., Goldman-Rakic P.S. Widespread origin of the primate mesofrontal dopamine system. Cerebral Cortex. 8:1998;321-345.
55. Zigmond M.J. Do compensatory processes underlie the preclinical phase of neurodegenerative disease? Insights from an animal model of Parkinsonism. Neurobiol. Dis. 4:1997;247-253.